禮來中國與騰訊(00700.HK)達成深度戰略合作
禮來中國表示,與騰訊(00700.HK)於7月12日達成深度戰略合作,基於禮來中國在醫療健康行業市場地位、行業洞察及對商業模式、藥物可及性創新的積極探索,結合騰訊在醫療健康領域深度佈局、數字化平臺和互聯網連接能力,雙方將通過雲服務、大數據分析、人工智能科技等技術賦能智慧醫療創新服務,打造一個以患者爲中心、各方共贏的智慧醫療生態系統。
騰訊醫療副總裁張猛表示,騰訊致力於成爲醫療行業的「數字化助手」,通過創新技術解決方案,推動醫療健康領域數字化升級,提升患者服務能力,期待通過與禮來合作,進一步挖掘人工智能、大數據分析和雲計算等創新技術的潛能。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.